We are live on ! Find out more
SNDX icon

Syndax Pharmaceuticals
SNDX

142 hedge funds and large institutions have $1.03B invested in Syndax Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 55 funds opening new positions, 50 increasing their positions, 24 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 55 | Existing positions closed: 11

150% more funds holding in top 10

Funds holding in top 10: 2 → 5 (+3)

144% more call options, than puts

Call options by funds: $8.49M | Put options by funds: $3.48M

110% more capital invested

Capital invested by funds: $493M → $1.03B (+$541M)

108% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 24

43% more funds holding

Funds holding: 99 → 142 (+43)

11.63% more ownership

Funds ownership: 88.81% → 100.43% (+12%)

Holders
142
Holders Change
+43
Holders Change %
+43.43%
% of All Funds
2.51%
Holding in Top 10
5
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+150%
% of All Funds
0.09%
New
55
Increased
50
Reduced
24
Closed
11
Calls
$8.49M
Puts
$3.48M
Net Calls
+$5.01M
Net Calls Change
+$5.13M

Top Buyers

1
Citadel Advisors
Citadel Advisors
Florida
+$32.1M
2
APM
Avidity Partners Management
Texas
+$30.2M
3
EAM
Eventide Asset Management
Massachusetts
+$25.9M
4
HM
HealthCor Management
New York
+$21.5M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$20.3M

Top Sellers

1
BI
BVF Inc
California
-$33M
2
MAM
MPM Asset Management
Massachusetts
-$27.2M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$14.8M
4
CS
Candriam SCA
Luxembourg
-$6.9M
5
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$2.51M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Investments
26
Two Sigma Investments
New York
$13.2M +$7.64M +368,182 +162%
Goldman Sachs
27
Goldman Sachs
New York
$12.3M +$6.27M +302,464 +120%
ACP
28
Acuta Capital Partners
California
$10.4M +$4.66M +224,756 +93%
Geode Capital Management
29
Geode Capital Management
Massachusetts
$10.3M +$1.06M +51,163 +12%
ACA
30
Avoro Capital Advisors
New York
$10M +$9.33M +450,000 New
CC
31
Casdin Capital
New York
$10M +$9.33M +450,000 New
SI
32
Sofinnova Investments
California
$8.29M +$7.73M +372,909 New
Northern Trust
33
Northern Trust
Illinois
$7.74M +$142K +6,864 +2%
CC
34
Commodore Capital
New York
$7.35M +$6.85M +330,315 New
Invesco
35
Invesco
Georgia
$6.95M +$5.12M +247,025 +377%
PA
36
Perceptive Advisors
New York
$6.67M +$6.22M +300,000 New
PAI
37
Palo Alto Investors
California
$5.88M +$1.36M +65,800 +33%
ACM
38
Altium Capital Management
New York
$5.86M +$5.47M +263,596 New
Charles Schwab
39
Charles Schwab
California
$4.33M +$226K +10,900 +6%
Marshall Wace
40
Marshall Wace
United Kingdom
$4.26M +$3.98M +191,788 New
Macquarie Group
41
Macquarie Group
Australia
$4M – – –
VOYA Investment Management
42
VOYA Investment Management
Georgia
$3.87M +$3.61M +174,103 New
T. Rowe Price Associates
43
T. Rowe Price Associates
Maryland
$3.81M +$3.56M +171,439 New
SCM
44
Sio Capital Management
New York
$3.78M +$3.43M +165,346 +3,448%
Hudson Bay Capital Management
45
Hudson Bay Capital Management
Connecticut
$3.56M -$2.38M -115,000 -42%
SSA
46
Schonfeld Strategic Advisors
New York
$3.5M +$2.83M +136,314 +655%
N
47
Nuveen
North Carolina
$3.48M -$628K -30,303 -16%
MS
48
Maven Securities
Jersey
$3.43M +$3.11M +150,000 New
IC
49
Ikarian Capital
Texas
$3.13M +$2.92M +140,913 New
Bank of New York Mellon
50
Bank of New York Mellon
New York
$2.9M +$559K +26,956 +26%
1
2
3 4 5

SNDX Hedge Fund Activity: Q4 2020 in Review

142 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q4 2020, worth a combined $1.03B — up 110% from $493M a quarter earlier.

Buyers outnumbered sellers: 55 funds opened new SNDX positions and 11 closed out — a net gain of 44 holders — while 50 added to existing stakes and 24 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $32.1M. The largest seller was BVF Inc, cutting an estimated $33M.

  • 142 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q4 2020, up from 99 in Q3 2020.
  • Funds reported $1.03B of Syndax Pharmaceuticals stock for Q4 2020, up 110% quarter-over-quarter.
  • 55 funds opened new Syndax Pharmaceuticals positions in Q4 2020 and 11 closed out, a net change of +44 holders.
  • The largest Syndax Pharmaceuticals buyer in Q4 2020 was Citadel Advisors, an estimated $32.1M added.
  • The largest Syndax Pharmaceuticals seller in Q4 2020 was BVF Inc, an estimated $33M sold.

Based on aggregated 13F filings for Q4 2020.